Skip to main content

Merck

MaterialsDarmstadt, Germany· One of 931 Materials companies tracked by AMPulse

Provides life science materials and technologies including bioinks and 3D printing solutions for pharmaceutical and bioprinting applications, enabling personalized medicine and drug development.

CEO / Founder
Belén Garijo
Team Size
10000+
Stage
Active

Technology & Products

Key Products

Bioinks; 3D printing materials for tablets; Life science reagents; Pharmaceutical development tools

Technological Advantage

Proprietary materials and processes for bioprinting and pharmaceutical 3D printing, supported by a global R&D network and regulatory expertise in GMP standards.

Differentiation

Value Proposition

Accelerates drug development and bioprinting research through high-quality materials and integrated 3D printing technologies, reducing time-to-market for therapies and enabling customized formulations.

How They Differentiate

Offers a broad portfolio of 300,000+ life science products combined with 3D printing capabilities, unlike pure-play bioprinting startups, providing integrated solutions from materials to manufacturing.

Market & Competition

Target Customers

Pharmaceutical companies, research institutions, biotech firms, and academic labs

Industry Verticals

Pharmaceutical; Biotechnology; Medical Research; Healthcare

Competitors

Cellink; Organovo; Allevi

Growth & Milestones

Growth Metrics

Merck's Life Science business, which includes bioprinting and 3D cell culture products, reported sales growth of 6.4% in 2023, with the Process Solutions segment (encompassing bioprocessing and related technologies) showing strong demand driven by advancements in personalized medicine and drug development.

Major Milestones

2015: Merger of Merck Millipore and Sigma-Aldrich; 2020: Partnership with AMCM for 3D-printed tablets; Establishment of 3D Technologies (3DT) organization

Notable Customers

Research institutions and pharmaceutical companies using Merck's bioprinting solutions include Harvard University, MIT, Johnson & Johnson, and Roche, as referenced in case studies and collaborations for drug development and tissue engineering applications.